Genetics Generation Advancement Corp.
Genetics Generation Advancement Corp. provides genetic testing and informatics services in Taiwan. The company offers testing services, including pre-implantation, prenatal, newborn medical examination, health management, reproductive medicine testing, obstetrics and gynecology testing, and neonatology and pediatrics testing, as well as gastroenterology, hepatology, oncology, and medical research… Read more
Genetics Generation Advancement Corp. (4160) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, Genetics Generation Advancement Corp. (4160) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Genetics Generation Advancement Corp. - Net Assets Trend (None–None)
This chart illustrates how Genetics Generation Advancement Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genetics Generation Advancement Corp. (None–None)
The table below shows the annual net assets of Genetics Generation Advancement Corp. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Genetics Generation Advancement Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Genetics Generation Advancement Corp. Competitors by Market Cap
The table below lists competitors of Genetics Generation Advancement Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AVIC Fund Management Co. Ltd.- AVIC Jingneng Photovoltaic Close Fund
SHG:508096
|
$13.05K |
|
LOTUSDEV
NSE:LOTUSDEV
|
$13.06K |
|
Wonder Pets Enterprises Corporation
TWO:6968
|
$13.06K |
|
Resource Capital Gold Corp
PINK:GDPEF
|
$13.06K |
|
Clearwise AG
DU:ABO
|
$13.02K |
|
Thai Oil PCL
STU:LQZ
|
$13.02K |
|
JSW Cement Ltd
NSE:JSWCEMENT
|
$13.01K |
|
Glen Eagle Resources Inc
PINK:GERFF
|
$13.01K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genetics Generation Advancement Corp.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Genetics Generation Advancement Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Genetics Generation Advancement Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Genetics Generation Advancement Corp.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $488,063,857
- Average return on equity (ROE) among peers: 1.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genetics Generation Advancement Corp. (4160) | NT$- | N/A | N/A | $13.03K |
| Bionet (1784) | $1.32 Billion | 2.02% | 0.36x | $107.18 Million |
| DIVA Laboratories Ltd (4153) | $1.02 Billion | 4.89% | 0.23x | $25.67 Million |
| Kim Forest Enterprise Co., Ltd. (6645) | $32.49 Million | 0.00% | 7.10x | $20.40 Million |
| Welgene Biotech Co.Ltd. (6661) | $246.55 Million | 11.49% | 0.47x | $3.31 Million |
| Puriblood Medical Co., Ltd. (6847) | $175.40 Million | -3.06% | 0.48x | $13.28 Million |
| TFBS Bioscience Inc. (6939) | $247.95 Million | 0.12% | 0.16x | $5.40K |
| Pharmigene, Inc. (7595) | $382.22 Million | -6.13% | 0.10x | $10.10 Million |